RPR121056-d3

RPR121056-d3 is the deuterium labeled RPR121056. RPR121056 is a metabolite of Irinotecan (HY-16562), which is generated by CYP3A4. Irinotecan (CPT-11) is an antineoplastic agent that inhibits topoisomerase type I, causing cell death, and is widely used in the treatment of colorectal cancer. Irinotecan also directly inhibits AChE[1][2].

Product Specifications

CAS Number

[1217816-76-6]

UNSPSC

12352005

Target

Cholinesterase (ChE) ; Isotope-Labeled Compounds; Topoisomerase

Related Pathways

Cell Cycle/DNA Damage; Neuronal Signaling; Others

Applications

Cancer-programmed cell death

Field of Research

Cancer

Solubility

10 mM in DMSO

Smiles

C(C([2H])([2H])[2H])C1=C2C(C=3N(C2)C(=O)C4=C(C3)[C@](CC)(O)C(=O)OC4)=NC=5C1=CC(OC(=O)N6CCC(NCCCCC(O)=O)CC6)=CC5

Molecular Formula

C33H35D3N4O8

Molecular Weight

621.70

References & Citations

[1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53 (2) :211-216.|[2]Alvau MD, et al. Enzyme-Based Electrochemical Biosensor for Therapeutic Drug Monitoring of Anticancer Drug Irinotecan. Anal Chem. 2018 May 15;90 (10) :6012-6019.